Affiliation:
1. 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Abstract
Summary:
In this issue, Rubinson, Tanaka, and colleagues demonstrate that differences among G12C inhibitors rely on their ability to covalently bind not only G12C mutant KRAS but also NRAS and HRAS, proposing sotorasib as a potent NRAS G12C inhibitor.
See related article by Rubinson et al., p. 727 (6).
Publisher
American Association for Cancer Research (AACR)
Reference10 articles.
1. Cancer statistics, 2024;Siegel;CA Cancer J Clin,2024
2. Treatment strategies for KRAS-mutated non-small-cell lung cancer;O'Sullivan;Cancers,2023
3. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation;Sacher;N Engl J Med,2023
4. Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C;Weiss;Cancer Discov,2022
5. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS;Schulze;Science,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献